Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers.

Rosa Falcone,Marco Filetti,Pasquale Lombardi,Valeria Altamura,Francesco Paroni Sterbini,Giovanni Scambia,Gennaro Daniele

Exploration of targeted anti-tumor therapy（2023）

引用 0|浏览15

暂无评分

摘要

This analysis provides clinical and molecular details about the phenotypes of ARID1A cancers, in particular the subgroup of gynecologic cancers. The high frequency of concurrent mutations in the phosphoinositide 3-kinase (PI3K) pathway among endometrioid endometrial cancers may support the proposal of a new treatment strategy based on the combination of ataxia telangiectasia and Rad3-related (ATR) inhibitor and PIK3CA inhibitor.

查看译文

关键词

at-rich interaction domain 1a,cancer,mutation,target

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要